The Treatment of Secondary Hemochromatosis
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Because secondary hemochromatosis is due to hereditary or acquired anemia, phlebotomy is not a suitable means of removing excess iron in this situation. Rather, the treatment is based on the targeted elimination of iron by means of iron chelators. METHODS: Selective review of the literature. RESULTS: Disorders causing secondary hemochromatosis (e.g., thalassemia) are characterized by ineffective erythropoiesis leading to increased duodenal uptake of iron. Most patients are also chronically transfusion-dependent and receive 200-250 mg of iron with each transfused unit of packed red blood cells. As the excess iron cannot be actively excreted, iron overload ensues, which can cause organ damage. Most patients with this condition in Germany are elderly persons with myelodysplastic syndromes (MDS). The standard treatment to date, parenterally administered deferoxamine, is often hampered by poor compliance. In September 2006, a new oral iron chelator, deferasirox, was approved for use in Germany. According to current findings, this medication is safe, except for a low risk of renal or hepatic failure. CONCLUSIONS: Iron chelation is a treatment option not only for thalassemia patients, but also for those with lower-risk MDS who can be expected to need several years of transfusion therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin
Tanno, T., Bhanu, N. V., Oneal, P. A., Goh, S.-H., Staker, P., Lee, Y. T., Moroney, J. W., Reed, C. H., Luban, N. L., Wang, R.-H., et al. (2007) · Nature Medicine · doi:10.1038/nm1629 · Cited by 854
Cited by
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361
Iron metabolism: pathophysiology and pharmacology
Roemhild, K., von Maltzahn, F., Weiskirchen, R., Knüchel, R., von Stillfried, S., & Lammers, T. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.05.001 · Cited by 302
Hypoxia-inducible factors link iron homeostasis and erythropoiesis
Shah, Y. M., & Xie, L. (2014) · Gastroenterology · doi:10.1053/j.gastro.2013.12.031 · Cited by 187
The effect of abnormal iron metabolism on osteoporosis
Che, J., Yang, J., Zhao, B., Zhang, G., Wang, L., Peng, S., & Shang, P. (2020) · Biological Trace Element Research · doi:10.1007/s12011-019-01867-4 · Cited by 113
Iron and genome stability: an update
Prá, D., Franke, S. I. R., Henriques, J. A. P., & Fenech, M. (2012) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2012.02.001 · Cited by 91
Metadata
- Authors
- Gattermann, N.
- Venue
- Deutsches Ärzteblatt international
- Publisher
- Deutscher Arzte-Verlag GmbH
- Published
- 2009-07-24
- Volume
- 106
- Issue
- 30
- Pages
- 499-504, I
- ISSN
- 1866-0452 (ISSN-L)
- OpenAlex
- W2129719369
- Cited by
- 76
- References
- 1
- FWCI
- 3.57
- Type
- journal article
- Language
- de
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Treatment of Secondary Hemochromatosis. https://app.cochat.ai/papers/10.3238/arztebl.2009.0499
- The paper
- Gattermann, N. (2009). The Treatment of Secondary Hemochromatosis. Deutsches Ärzteblatt international. https://doi.org/10.3238/arztebl.2009.0499
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.